Intelligence Platform

Patents

Browse 379 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9574192

Serapina1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9566295

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9566340

Monomers and oligonucleotides comprising cycloaddition adduct(s)

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9506067

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9463247

Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active a

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9453222

Ligand-conjugated monomers

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9441225

Compositions and methods for inhibiting expression of factor V

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9422562

Compositions and methods for inhibiting expression of CD274/PD-L1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9415109

Stable non-aggregating nucleic acid lipid particle formulations

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9399775

RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) ass

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9394540

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9376680

Serpinc1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9370582

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9370581

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9352048

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. · Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9339513

Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

Alnylam Pharmaceuticals, Inc. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9322018

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9315813

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9290760

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9260718

Compositions and methods for inhibiting expression of the PCSK9 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9254327

Methods and compositions for delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9249415

Complement component C5 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9234196

Compositions and methods for inhibiting expression of transthyretin

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9228188

Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-relat

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted